Abstract
More and more studies have investigated the effects of Ezrin expression level on the prognostic role in various tumors. However, the results remain controversial rather than conclusive. Here, we performed a systematic review and meta-analysis to evaluate the correlation of Ezrin expression with the prognosis in various tumors. the pooled hazard ratios (HR) with the corresponding 95% confidence intervals (95% CI) were calculated to evaluate the degree of the association. The overall results of fifty-five studies with 6675 patients showed that elevated Ezrin expression was associated with a worse prognosis in patients with cancers, with the pooled HRs of 1.86 (95% CI: 1.51–2.31, P < 0.001) for over survival (OS), 2.55 (95% CI: 2.14–3.05, P < 0.001) for disease-specific survival (DFS) and 2.02 (95% CI: 1.13–3.63, P = 0.018) for disease-specific survival (DSS)/metastasis-free survival (MFS) by the random, fixed and random effect model respectively. Similar results were also observed in the stratified analyses by tumor types, ethnicity background and sample source. This meta-analysis suggests that Ezrin may be a potential prognostic marker in cancer patients. High Ezrin is associated with a poor prognosis in a variety of solid tumors.
Highlights
Ezrin is an important member of the ERM (Ezrin-radixin-moesin) cytoskeleton-associated proteins family, which started to look like a transit protein between membrane proteins and actin filaments[1,2]
There were one article[47] investigated in two different types of intrahepatic cholangiocarcinoma and another one[50] investigated in two independent patient cohorts, so we considered the data from these studies as an individual separately
In the sub-group analyses based on sample source, the results demonstrated that high Ezrin expression had a worse prognosis for over survival (OS) (HR = 2.32, 95% confidence intervals (95% CI):1.84–2.92, P < 0 .001) and disease-specific survival (DSS)/metastasis-free survival (MFS) (HR = 3.82, 95% CI: 2.20–6.64, P < 0 .001) from formalin-fixed and paraffin-embedded (FFPE) samples, but not those from tissue microarray (TMA) ones (HR = 1.02, 95%CI: 0.64–1.61, P = 0.947; hazard ratios (HR) = 1 .12, 95%CI: 0.46–2.70, P = 0 806, respectively)
Summary
Ezrin is an important member of the ERM (Ezrin-radixin-moesin) cytoskeleton-associated proteins family, which started to look like a transit protein between membrane proteins and actin filaments[1,2]. Recent studies have revealed that Ezrin is an important signaling molecule that is well-documented to be associated with many cellular processes, including cell proliferation, cell adhesion, cell motility, signal transduction and so on[3,4,5,6], all of those processes play a vital role in tumorigenesis, development, invasion and metastasis in a variety of human malignancies[7,8,9,10,11,12,13,14]. In terms of the limits of the single study, as well as in order to better understanding the significance of Ezrin expression in the prognosis of cancer patients, performing a comprehensive meta-analysis to evaluate the published studies is necessary. In the present meta-analysis, the aim is to assess the correlation between Ezrin expression and the survival outcomes in cancer patients via collecting global related literatures to carry out a systematic analysis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
